Inhibrx Biosciences (INBX) FCF Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of FCF Margin data on file, last reported at 2302.46% in Q2 2025.

• On a quarterly basis, FCF Margin rose 5495554.0% year-over-year to 2302.46% in Q2 2025; TTM through Dec 2025 was 9273.21%, a 146866.0% increase from a year earlier, with the FY2025 full-year figure at 9986.54%, up 8851646.0% from the prior year.
• FCF Margin for Q2 2025 stood at 2302.46%, up from 42769.0% in the prior quarter.
• Over the last five years, FCF Margin for INBX reached as high as 2302.46% in Q2 2025 and fell as low as 57258.0% in Q2 2024.
• Historically, FCF Margin has averaged 30513.76% across 3 years, with a median of 42769.0% in 2024.
• Across the five-year window, FCF Margin slumped 3908093 bps in 2024 and soared 5495554 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 3688.07% in 2023, then tumbled by 1060 bps to 42769.0% in 2024, then soared by 95 bps to 2302.46% in 2025.
• Per Business Quant data, the three most recent FCF Margin figures were 2302.46% in Q2 2025, 42769.0% in Q4 2024, and 57258.0% in Q2 2024.